APLI.H — Appili Therapeutics Cashflow Statement
0.000.00%
- CA$0.66m
- CA$13.85m
- CA$0.24m
Annual cashflow statement for Appili Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -25.1 | -9.24 | -3.78 | -2.62 | -4.24 |
| Depreciation | |||||
| Non-Cash Items | 3.54 | 2.37 | 0.641 | 3.71 | 0.799 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.49 | -3.24 | 0.661 | -0.226 | 2.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -19.1 | -10.1 | -2.46 | 0.869 | -1.34 |
| Capital Expenditures | 0 | -0.003 | -0.03 | -0.002 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5.06 | 0 | 0.001 | 0 | — |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 5.06 | -0.003 | -0.029 | -0.002 | 0 |
| Financing Cash Flow Items | -1.31 | -1.01 | -0.082 | -0.065 | -0.069 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.56 | 5.91 | 0.122 | 0.194 | 0.151 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.4 | -4.2 | -2.37 | 1.13 | -1.19 |